<DOC>
	<DOC>NCT00480636</DOC>
	<brief_summary>To collect postmarketing data about Fragmin safety and efficacy in the treatment of deep vein thrombosis with or without pulmonary embolism in cancer patients.</brief_summary>
	<brief_title>Fragmin In The Treatment Of Acute Deep-Vein Thrombosis With Or Without Pulmonary Embolism In Cancer Patients</brief_title>
	<detailed_description>Method: consecutive patient sampling. Patients were (are) included in the study in consecutive manner if they fulfilled the inclusion criteria and any of the exclusion criteria were not present.</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
	<criteria>Male or female patient of 18 70 years of age. Cancer patient with proven deepvein thrombosis with or without pulmonary embolism confirmed by combination of clinical signs and symptoms, pulmonary hypertension on echocardiogram, Xray examination of the lung and eventually perfusion/ventilation scan of the lung. Bleeding Hypersensitivity to FRAGMINÂ® or other lowmolecular weight heparins. Serum creatinine level &gt; 150 umol/l. Platelet count of less than 100 000 per cubic millimeter at the beginning of the therapy. Patient on oral anticoagulation therapy in the last 7 days.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>